A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy
Valentin Garcia Gutierrez,Andres Novo,Antonio Jimenez-Velasco,Luis Felipe Casado Montero,Fermin Sanchez-Guijo,Raul Perez Lopez,Santiago Osorio-Prendes, Lakhwani,Angel Ramirez Payer,Guillermo Orti,Maria Teresa Gomez-Casares,Juan Manuel Alonso,Manuel Perez-Encinas,Rolando Vallansot,Ernesto Perez Persona, Maria Angeles Portero Frias,Maria Jose Ramirez Sanchez,Maria Alicia Senin,Gonzalo Caballero,Soledad Noya,Concepcion Boque,Maribel Mata, Mario Romo,Juan Luis Steegmann,Juan Carlos Hernandez-Boluda Blood（2017）
AI 理解论文
溯源树
样例
